Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › VT › Burlington › NPI 1568419976
Hospital

University of Vermont Medical Center INC

University of Vermont Medical Center INC was paid $790K by Medicaid between Jan 2018 and Nov 2024, across 27 billing codes. Its largest line is 67028, Intravitreal injection of a pharmacologic agent — 44% of everything it billed.

33Billing provider infoUNIVERSITY OF VERMONT MEDICAL CENTER INC
BURLINGTON, VT 05401
33aNPI1568419976assigned 05/30/2006
28Total paid$790K
24GClaims31,808
24DCodes billed27
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service

Paid by month

$0$20K$40K$60K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20185,583$89K
20195,877$38K
20201,549$39K
20213,525$77K
20225,959$136K
20235,985$278K
2024incomplete3,330$133K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
67028 Intravitreal injection of a pharmacologic agent 44% 2,184 1,566 $350K
G0463 Hospital outpatient clinic visit for assessment and management of a patient 41% 22,380 15,463 $324K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 5.2% 263 216 $41K
J0178 Injection, aflibercept, 1 mg 3.4% 372 272 $27K
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 1.4% 41 39 $11K
80053 Comprehensive metabolic panel <1% 365 315 $7K
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity <1% 67 62 $7K
77080 <1% 227 181 $6K
92134 <1% 2,915 2,288 $5K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 1,191 986 $4K
36415 Collection of venous blood by venipuncture <1% 600 500 $3K
95811 <1% 12 12 $3K
15 more codes
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 32 $2K
81003 <1% 29 $894.16
93288 <1% 138 $667.38
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 31 $468.13
36416 <1% 70 $168.61
80048 Basic metabolic panel (calcium, ionized) <1% 13 $164.97
77091 <1% 261 $114.18
J0330 Injection, succinylcholine chloride, up to 20 mg <1% 52 $29.87
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 85 $23.19
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 12 $21.20
J7030 Infusion, normal saline solution , 1000 cc 0% 65 $0.00
C9257 Injection, bevacizumab, 0.25 mg 0% 17 $0.00
J2250 Injection, midazolam hydrochloride, per 1 mg 0% 82 $0.00
83036 Hemoglobin; glycosylated (A1C) 0% 55 $0.00
J3010 Injection, fentanyl citrate, 0.1 mg 0% 249 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialVINCENT, RICHARD (INTERIM CHIEF FINANCIAL OFFICER)
Same official

Other billing entities under VINCENT, RICHARD

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.